Advances in Endocrine Therapies 2005
Novel treatments targets & therapeutic potential
19th and 20th January 2005 - Workshop 18th January 2005
Kensington Marriott Hotel, London
**** CONFERENCE BROCHURE AVAILABLE NOW - REQUEST YOURS TODAY ****
In such a wide reaching industry, it is important to focus on key areas of
progression. At this conference delegates will learn about new developments
in significant areas of the market, from diabetes and obesity to cancer and
hormone replacement therapies.
THEMES WILL INCLUDE:
**New developments in diabetes - how can your company enter this rapidly
growing & changing market?
**Learn about new approaches to weight loss & emerging therapies for
metabolic diseases
**Advice on how your company can become an industry leader in the market for
infertility drugs
**Improve your clinical trials for osteoporosis & learn about the
alternatives to HRT
**Achieve more efficient insulin delivery - optimise your potential success
**Benefit from the best practice case studies: Forteo; Passport;
Somatostatin
KEY SPEAKERS
**Dr. Anthony Beardsworth, Lead Physician, Primary Care, Eli Lilly
**Dr. Monique Berwaer, Head, Metabolic Diseases, Johnson & Johnson
**Caroline Turnbull, Armidex Brand Leader, AstraZeneca
**Dr. Desmond Thompson, Senior Scientific Director, Merck
**Dr. Milan Zdravkovic, International Medical Officer, NovoNordisk
**Dr. Manfred Ganz, Director, Head of Medical Assessment Strategy and
Business Development, Roche
**Dr. Bharat Tewarie, Executive Vice President, Reproductive Health, Serono
**Dr. Eric Tomlinson, Chief Executive Officer, Altea Therapeutics
**Dr. George Merriam, Scientific Advisor, Theratechnologies
**Dr. Gerald Bernstein, Vice President, Medical Affairs, Generex
Biotechnology
**Dr. Alan Davis, European Medical Director, Kendle
------------------
WHO SHOULD ATTEND
------------------
**Vice President, Global Medical Endocrinology
**Senior Vice President, Endocrine Business
**Senior Medical Director, Endocrinology
**Director, Endocrinology & Metabolism
**Senior Director, Metabolic Diseases
**Global Head, Diabetes & Clinical Research
**Vice President, Diabetes
**Vice President, Glucose Monitoring Systems
**Vice President, Cardiovascular & Metabolism
**Executive Vice President, Women's Health
**Vice President, Reproductive Health
==================================================================
This event will also feature: Pre-conference Interactive Workshop
==================================================================
Glucose Sensing & Insulin Pumps
Workshop leaders: Ian Tilly, Glucose Sensor Specialist, Medtronic MiniMed Uk
& Ireland
Susan Judge, Diabetes Specialist, Nurse & Education
Co-ordinator.
Strategies for pricing and market access of innovative endocrine therapies
Led by: Christian Schuler, Director Health Sciences Division, Simon-Kucher &
Partners
---------------------
DELEGATE REGISTRATION
---------------------
Places at this event are strictly limited so BOOK YOUR PLACE NOW.
To make a booking on this event, please contact me via phone or email. Book
early to secure a place.
- PRICING -
Attend the:
2 Day conference with interactive workshop - ONLY GBP1600 plus VAT
2 Day conference - ONLY GBP1299 plus VAT
Workshop only - ONLY GBP650 plus VAT
- BOOKINGS -
Booking is easy, simply contact me:
Joe Stone
Account Manager - Conference Division
Visiongain B2B Conferences
Tel. +44(0)20 8767 6711
Fax. +44(0)20 8767 5001
mailto:joe.stone@visiongain.com
B2B Conferences is part of the Visiongain Group
**** FULL CONFERENCE AGENDA BELOW ****
===================================
PRE-CONFERENCE INTERACTIVE WORKSHOP
Tuesday 18th January 2005
===================================
Glucose sensing & insulin pumps:
optimise diabetes care & analyse pump therapy
Led by: Ian Tilly, Glucose Sensor Specialist & Susan Judge,
Diabetes Specialist, Nurse & Education Co-ordinator,
Medronic MiniMed UK & Ireland
Main topics of discussion:
. Validation of new treatment efficacy in improving
glycaemic control.
. Enhancing the value of clinical trials.
. Features and benefits of insulin pump therapy.
. Combining sensors & pumps - creating an artificial
pancreas.
Strategies for pricing and market access of innovative endocrine therapies
Led by: Christian Schuler, Director Health Sciences Division, Simon-Kucher &
Partners
Strategies for Pricing and Market Access of Innovative
Endocrine Therapies
. Challenges within the endocrine market environment
. P&R Environment for innovative endocrine therapies
. Key learnings from recent product launches
. The concept of value based pricing
. Pricing techniques
===================================
Day One Wednesday 19th January 2005
===================================
09:00 Registration and coffee
09:30 Opening remarks from the chair
09:40 An Overview of the Industry
Dr. Ray Scraggs, Head Consultant at visiongain, will introduce
questionnaires which give you the chance to make comments
on the Endocrine Industry. The findings will be discussed at
the end of the day in a panel session.
NEW DEVELOPMENTS IN DIABETES
09:50 The Future of the Diabetes Market: What are the
Possibilities for Your Company?
. How to rise to the challenge for advanced and effective treatment
. Impaired metabolism: how to cope with complications
. Tactics for novel target discovery
. Strategies for genomics based drug discovery
. Tips on improving diabetes care - decrease complications and gain
metabolic control
. How to avoid microvascular complications
. Different approaches to post infection therapies
Dr. Manfred Ganz, Director, Head of Medical Assessment Strategy and
Business Development Global Diabetes Care
Roche Diagnostics GmbH
10:30 CASE STUDY: 11 bHSD1 - A Novel Target in the treatment of
Diabetes & Metablic Symdrome
. The potential of selective 11 bHSD1 inhibition in the treatment of
diabetes and associated complications
. The need for a better understanding of the endocrine function of
adipose tissue
. Cortisol induced insulin resistance in man
. HSD1 and metabolic syndrome: what are the possibilities for your
company?
. Effect of selective HSD1 inhibition in diabetic rodents: analysis of
results
. The importance of 11beta-HSD1 in the development of metabolic
syndrome - examination of data from studies of obese rodents
Dr. Monique Berwaer, Head, Metabolic Diseases
Johnson & Johnson
11:10 Morning Coffee
11:30 CASE STUDY: Incretin Mimetics - GLP-1 and Liraglutide
. Mechanism of action: increasing insulin secretion; reducing
glucagon production; delaying gastric emptying
. What are the potential applications?
. Possible multiple benefits including weight loss vs drawbacks of
delivery by injection
. Analysis of results of preclinical testing
. Potential for sustained action - improving patient care
Dr. Milan Zdravkovic, International Medical Officer
Novo Nordisk
12:10 Innovations in Insulin Delivery: Possibilities for New
Technologies
. What will be the future of the insulin pill? - replacing first phase
insulin response
. Recent advances in insulin pump therapy - analysis of new
possibilities & assessment of options
. The impact of oral insulin spray on the market
. Updates on FDA approval for inhaled insulin: overcoming long
term effects
Dr. Gerald Bernstein, Vice President, Medical Affairs
Generex Biotechnology
12:50 Lunch
14:00 CASE STUDY: Passport - The Potential for Transdermal Insulin
Delivery
. Mechanism of action: a sonic applicator deploying
. ultrasound & introducing drug molecules through the skin
Added benefits of combined skin patch and insulin pill
. Increasing administration length: new development of a 24 hour
patch
. Advantages over alternatives - achieve steady and accurate
delivery of your diabetes drugs
. Improve patient compliance - a non-invasive, pain and hassle free
treatment
. Market potential - a cost-effective, efficient treatment without
troublesome side-effects
Dr. Eric Tomlinson, Chief Executive Officer
Altea Therapeutics
NOVEL TREATMENTS IN THE OBESITY MARKET
14:40 New Approaches to Weight Loss Drugs: Responding to Gaps
in the Obesity Market
. Current drugs and their limitations: lessons to be learnt from the
past
. How can body weight be regulated and modified?
. New approaches for discovering novel targets for the treatment of
obesity
Jon Arch, Professorial Research Fellow, Deputy Director of Metabolic
Research
University of Buckingham
15:20 Afternoon Tea
THE ENDOCRINE TREATMENT OF BREAST CANCER
15:40 CASE STUDY: Armidex - the Future of Treatment &
Prevention of Breast Cancer
. The first aromatase inhibitor to be approved - effect on your
market
. Current market for breast cancer drugs - where can you capture a
share?
. Developments in endocrine agents: steps towards the goal of
breast cancer prevention
. Comparison of aromatase inhibitors with tamoxifen - how long
before tamoxifen is obsolete?
. Analysis of results of recent clinical studies
Caroline Turnbull, Arimidex Brand Leader
AstraZeneca
16:20 Questions and Discussion
16:30 Summation of day one from conference chair
16:40 Close of Day One
==================================
Day Two Thursday 20th January 2005
==================================
08:30 Registration and Coffee
09:00 Opening remarks from the Chair
DEVELOPMENTS IN GROWTH HORMONE THERAPIES
09:10 KEYNOTE SESSION
MINI SYMPOSIUM: GROWTH HORMONECLINICAL INSIGHTS & MECHANISMS
With invited manufacturers of growth hormone and growth
hormone secretagogues
Led By: Dr. George Merriam
Scientific Advisor, Professor of Medicine
Theratechnologies, University of Washington
10:10 CASE STUDY: Somatostatin - Developments in the Treatment
of Acromegaly
. Mechanism of action of somatostatin analogues
. The need to improve clinical management of patients
. Addressing patient issues: appropriate dosing regimes & extended
duration preparations
. Defining the role of somatostatin analogues: checking & balancing
hormones & growth
. Advantages of multiple benefits: treating adverse clinical effects
of acromegaly
. SOM230: a new multiligand somatoststatin analogue - the
possibilities for future treatments
Dr. Herbert Schmid, Senior Research Investigator for Somatostatin Research
Novartis
10:50 Morning Coffee
ENDOCRINOLOGY AND WOMEN'S HEALTH ISSUES
11:10 The Endocrinology Of Ageing
. Ageing - the major driver in the endocrine industry: gain your share
of the market
. The underlying mechanisms responsible for reduction in strength,
frequency and production of hormones
. Future targets for age-related diseases: what are the opportunities
for your company?
Dr. Desmond Thompson, Senior Scientific Director
Merck
11:50 Delivering Clinical Trials for Osteoporosis: Improve your
Company's Studies
. Clinical trial metrics & management: ensure your osteoporosis trials
are efficient & cost effective
. Tips for long & short term studies
. Advice on recruiting & retaining trial subjects
. How to select appropriate clinical endpoints for your osteoporosis
trials
. Safety assessments & regulatory requirements: how do they affect
your studies?
Dr. Alan Davies, European Medical Director
Kendle
12:30 Lunch
14:00 CASE STUDY: Forteo - The First Bone Formation Agent in the
Treatment of Osteoporosis
. Mechanism of action: the use of recombinant human parathyroid
hormone: the potential to replace depleted bone stores
. Multiple benefits: forming new bone, increasing bone density
and improving bone strength
. Overcoming possible side effects - what can be done to improve
patient care?
. The proven success of Forteo: results from the fracture
prevention trial
. Launch in India - tracking the success
Dr. Anthony Beardsworth, Lead Physician, Primary Care
Eli Lilly
14:40 CASE STUDY: Microencapsulated r-FSH - Novel Treatments
for Infertility
. The growing market for the treatment of infertility - tips for market
share
. Learn from the experts - how Serono became market leaders for
the treatment of infertility with Gonal-F
. Gonal-f(R) RFF Pen: the first and only prefilled and ready-to-use
multi-dose FSH in the US
. Benefits of rFSH over urinary products - consistent potency & less
contaminants
. Analysis and updates of recent clinical trials
. Future targets for the treatment of infertility
Dr. Bharat Tewarie, Executive Vice-President, Reproductive Health
Serono
15:20 Afternoon Tea
RECENT ADVANCES IN HYPERTENSION
16:00 CASE STUDY: SPP100 (Aliskiren) - A Novel Treatment for
Hypertension & Related Conditions
. A new mode of action for the treatment of hypertension & end
organ damage
. Analysis of results of recent clinical trials & studies: Aliskiren Vs
Irbesartan
. New technical achievements: producing a commercially viable
manufacturing process
. Possibilites for multiple treatment benefits
Dr. Hans Brunner, Medical Advisor
Speedel
16:40 DISCUSSION: Attendees Perspective
Presentation and discussion of the questionnaire results led by Dr. Ray
Scraggs. This will involve some freeform discussion & the opportunity
to engage in knowledge sharing with fellow professionals.
17:00 Chairman summation and close of conference
Terms & Conditions
NB - Due to high demand, we do not 'reserve' or 'hold' places - a request
for an invoice to be raised will be treated as an official booking and will
be subject to the cancellation policy as outlined below.
Cancellations/substitutions and name changes: All bookings carry a 50%
liability after the booking has been made, by post fax, email or web. There
will be no refunds for cancellations received on or after one month before
the start of the conference (e.g. cancellation on or after 20th January for
a conference starting on 20th February). If you decide to cancel after this
date the full invoice remains payable. Conference notes, which are available
on the day, will be sent to you. Unfortunately we are not able to transfer
places between conferences and executive briefings. However if you are
unable to attend the event you may make a substitution/name change at any
time as long as we are informed in writing by e-mail, fax or post. Name
changes and substitutions must be from the same company and are not
transferable between companies or countries.
Indemnity: visiongain Ltd reserve the right to change the
conference/executive briefing content, timing, speakers or venue without
notice. The event may be postponed or cancelled due to acts of terrorism,
war, extreme weather conditions, industrial action, acts of God or any event
beyond the control of visiongain Ltd. If such a situation arises we will
endeavour to reschedule the event. However, visiongain Ltd cannot be held
responsible for any cost, damage or expenses, which may be incurred by the
customer as a consequence of the event being postponed or cancelled. We
therefore strongly advise all customers to take out insurance to cover the
cost of the registration, travel and expenses.
To unsubscribe please reply with unsubscribe in the subject line.
Data protection: Visiongain Ltd gathers and manages data in accordance with
the Data Protection Act 1998. Information contained about you may be used to
update you on visiongain Ltd products and services via post, telephone, fax
or email, unless you state otherwise. If you wish your details to be
amended, please send your request to the Database Manager, visiongain Ltd,
40 Tooting High Street, London, SW17 0RG. Alternatively please reply with
unsubscribe in the subject line. Please allow approximately 7 days for your
removal or update request, you may receive additional pieces of
communication from visiongain Ltd during the transitional period, whilst the
changes come into effect.
